|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
US4889818A
(en)
|
1986-08-22 |
1989-12-26 |
Cetus Corporation |
Purified thermostable enzyme
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
AU4645697A
(en)
|
1996-09-11 |
1998-04-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aav4 vector and uses thereof
|
|
US6156303A
(en)
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
US7575924B2
(en)
|
2000-11-13 |
2009-08-18 |
Research Development Foundation |
Methods and compositions relating to improved lentiviral vectors and their applications
|
|
WO2002092134A1
(en)
|
2001-05-14 |
2002-11-21 |
Cell Genesys, Inc. |
Lentiviral vectors encoding clotting factors for gene therapy
|
|
ATE527347T1
(de)
|
2001-08-02 |
2011-10-15 |
Inst Clayton De La Rech |
Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
|
|
CA2462628C
(en)
|
2001-10-02 |
2019-08-20 |
Institut Clayton De La Recherche |
Restricted expression lentiviral vectors
|
|
CN103589692B
(zh)
|
2001-11-13 |
2018-07-24 |
宾夕法尼亚大学托管会 |
检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
|
|
EP1463805B1
(en)
|
2001-12-17 |
2014-10-22 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
|
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
GB0220467D0
(en)
|
2002-09-03 |
2002-10-09 |
Oxford Biomedica Ltd |
Composition
|
|
ES2348868T3
(es)
|
2002-12-13 |
2010-12-16 |
Genetix Pharmaceuticals Inc. |
Vectores retrovirales terapeuticos para terapia genica.
|
|
EP1668143B1
(en)
|
2003-09-30 |
2013-03-20 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
CA2569664C
(en)
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
DE23193606T1
(de)
|
2005-04-07 |
2024-02-15 |
The Trustees Of The University Of Pennsylvania |
Verfahren zur erhöhung der funktion eines aav-vektors
|
|
JP5639338B2
(ja)
|
2005-07-27 |
2014-12-10 |
プロチバ バイオセラピューティクス インコーポレイティッド |
リポソームの製造システムおよび製造方法
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
JP2007054069A
(ja)
|
2005-08-24 |
2007-03-08 |
Medizinische Hochschule Hannover |
自己不活性化レトロウイルスベクター
|
|
EP1757703A3
(en)
|
2005-08-24 |
2007-12-05 |
Medizinische Hochschule Hannover |
Self-inactivating retroviral vector
|
|
EP1757702A1
(en)
|
2005-08-24 |
2007-02-28 |
Medizinische Hochschule Hannover |
Self-inactivating gammaretroviral vector
|
|
EP2132322A4
(en)
|
2007-03-02 |
2013-02-20 |
Richmond Chemical Corp |
METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE
|
|
ES2708856T3
(es)
|
2007-08-03 |
2019-04-11 |
Pasteur Institut |
Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales
|
|
DK2197903T3
(en)
|
2007-09-04 |
2015-01-05 |
Us Gov Health & Human Serv |
Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
|
|
CA2720903C
(en)
|
2008-04-14 |
2019-01-15 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
AU2009303345B2
(en)
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
CN102421801B
(zh)
|
2009-03-10 |
2016-03-16 |
比奥根Ma公司 |
抗-bcma抗体
|
|
EP2414524B1
(en)
|
2009-04-03 |
2017-08-23 |
Centre National De La Recherche Scientifique |
Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
|
|
US20120164118A1
(en)
|
2009-05-04 |
2012-06-28 |
Fred Hutchinson Cancer Research Center |
Cocal vesiculovirus envelope pseudotyped retroviral vectors
|
|
KR20220038506A
(ko)
|
2009-06-10 |
2022-03-28 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
EP2451475A2
(en)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Self replicating rna molecules and uses thereof
|
|
US9255259B2
(en)
|
2010-02-09 |
2016-02-09 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
WO2012061814A1
(en)
|
2010-11-05 |
2012-05-10 |
Transgenomic, Inc. |
Pcr primers and methods for rapid and specific genotyping
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2714737A1
(en)
|
2011-05-27 |
2014-04-09 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
US20140359799A1
(en)
|
2011-12-23 |
2014-12-04 |
Case Western Reserve University |
Targeted gene modification using hybrid recombinant adeno-associated virus
|
|
US10066207B2
(en)
|
2012-04-18 |
2018-09-04 |
Board Of Trustees Of Michigan State University |
Natural killer cells with enhanced immune response
|
|
GB201212902D0
(en)
|
2012-07-20 |
2012-09-05 |
Univ Singapore |
Combinatoric encoding methods for microarrays
|
|
WO2014121005A1
(en)
|
2013-02-01 |
2014-08-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Retroviral vector packaging cell lines and methods of purifying and producing retroviral particles
|
|
CA2920539C
(en)
|
2013-08-08 |
2024-01-02 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
GB201318347D0
(en)
|
2013-10-16 |
2013-11-27 |
Ucl Business Plc |
Retroviral vectors
|
|
SG11201608701QA
(en)
|
2014-04-18 |
2016-11-29 |
Editas Medicine Inc |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
EP3805371A1
(en)
|
2014-05-15 |
2021-04-14 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
MX2018010484A
(es)
|
2016-03-04 |
2019-01-10 |
Editas Medicine Inc |
Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
|
|
PL3896091T3
(pl)
|
2016-08-10 |
2024-04-29 |
Legend Biotech Ireland Limited |
Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
|
|
AT519217B1
(de)
|
2016-10-04 |
2018-08-15 |
Carboncompetence Gmbh |
Vorrichtung und Verfahren zum Aufbringen einer Kohlenstoffschicht
|
|
EP3581190B1
(en)
|
2016-12-09 |
2021-03-10 |
ONK Therapeutics Limited |
Engineered natural killer cells and uses thereof
|
|
AU2018219895C1
(en)
*
|
2017-02-09 |
2024-10-03 |
Indapta Therapeutics, Inc. |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
|
EP3634437A4
(en)
|
2017-05-19 |
2020-11-18 |
Case Western Reserve University |
COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
|
|
WO2019010384A1
(en)
|
2017-07-07 |
2019-01-10 |
The Broad Institute, Inc. |
METHODS FOR DESIGNING GUIDE SEQUENCES FOR GUIDED NUCLEASES
|
|
BR112020011017A2
(pt)
|
2017-12-22 |
2020-11-17 |
Fate Therapeutics, Inc. |
células efetoras imunes intensificadas e uso das mesmas
|
|
AU2019243315A1
(en)
|
2018-03-29 |
2020-09-24 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
|
AU2019271366B2
(en)
|
2018-05-16 |
2026-02-26 |
Research Institute At Nationwide Children's Hospital |
Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins
|
|
ES3068417T3
(en)
|
2018-09-13 |
2026-05-29 |
Nkarta Inc |
Natural killer cell compositions and immunotherapy methods for treating a liver tumor
|
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
|
CN109652379B
(zh)
*
|
2018-12-29 |
2022-08-16 |
博生吉医药科技(苏州)有限公司 |
Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
|
|
BR112021016046A2
(pt)
|
2019-02-15 |
2021-11-09 |
Editas Medicine Inc |
Células assassinas naturais modificadas (nk) para imunoterapia
|
|
CN114174325A
(zh)
*
|
2019-06-04 |
2022-03-11 |
恩卡尔塔公司 |
用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
|
|
KR20220035190A
(ko)
|
2019-07-17 |
2022-03-21 |
페이트 세러퓨틱스, 인코포레이티드 |
면역 효과기 세포 조작 및 이의 용도
|
|
AU2020321354A1
(en)
|
2019-07-31 |
2022-03-03 |
Nkarta, Inc. |
Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells
|
|
US20220378831A1
(en)
|
2019-09-25 |
2022-12-01 |
Fate Therapeutics, Inc. |
Multi-targeting effector cells and use thereof
|
|
CN114867485A
(zh)
|
2019-10-31 |
2022-08-05 |
全国儿童医院研究所 |
Cd38敲除的原代和扩增的人nk细胞的生成
|
|
US20230272035A1
(en)
|
2019-12-05 |
2023-08-31 |
Vycellix, Inc. |
Modulators of the immune escape mechanism for universal cell therapy
|